ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,094.70
-0.57%
S&P ASX All Technology
3,747.70
0.46%
Brent Oil
69.625
0.52%
US Dollar vs AUD
1.57788
0.00%
Bitcoin
90,193.02
-0.48%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Alumis Inc (ALMS) Share Price

Alumis Inc

Alumis Inc (ALMS)

NASDAQ
4.72
0.13
(2.83%)
Closed 06 March 8:00AM
Delayed by 15 minutes
4.72
0.00
( 0.00% )
Pre Market: 8:21PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
4.72
Bid
1.91
Offer
5.22
Volume
-
0.00 Day's Range 0.00
4.36 52 Week Range 13.50
Market Cap
256.803M
Previous Close
4.72
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
183,034
Shares Outstanding
54,407,327
Dividend Yield
-
PE Ratio
-1.66
Earnings Per Share (EPS)
-2.85
Revenue
-
Net Profit
-154.99M

About Alumis Inc

Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor th... Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.alumis.com
Headquarters
Dover, Delaware, USA
Founded
-
Alumis Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALMS. The last closing price for Alumis was US$4.72. Over the last year, Alumis shares have traded in a share price range of US$ 4.36 to US$ 13.50.

Alumis currently has 54,407,327 shares in issue. The market capitalisation of Alumis is US$256.80 million. Alumis has a price to earnings ratio (PE ratio) of -1.66.

Ask ADVFN Intelligence (AI)

ALMS Latest News

More News

Form 425 - Prospectuses and communications, business combinations
Edgar (US Regulatory)
2 hours ago
ALMS (2.83%)

Form 425 - Prospectuses and communications, business combinations
Edgar (US Regulatory)
05 March 2025
ALMS (2.83%)

Form 8-K - Current report
Edgar (US Regulatory)
05 March 2025
ALMS (2.83%)

Form 8-K - Current report
Edgar (US Regulatory)
22 February 2025
ALMS (2.83%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-0.2114164904864.734.884.361423704.64352993CS
4-2.52-34.80662983437.247.244.362710085.20060815CS
12-4.28-47.555555555699.24.361830346.37550432CS
26-7.225-60.485558811211.94513.114.361663858.59982042CS
52-8.78-65.03703703713.513.54.361658399.68216189CS
156-8.78-65.03703703713.513.54.361658399.68216189CS
260-8.78-65.03703703713.513.54.361658399.68216189CS

ALMS - Frequently Asked Questions (FAQ)

What is the current Alumis share price?
The current share price of Alumis is US$ 4.72
How many Alumis shares are in issue?
Alumis has 54,407,327 shares in issue
What is the market cap of Alumis?
The market capitalisation of Alumis is USD 256.8M
What is the 1 year trading range for Alumis share price?
Alumis has traded in the range of US$ 4.36 to US$ 13.50 during the past year
What is the PE ratio of Alumis?
The price to earnings ratio of Alumis is -1.66
What is the reporting currency for Alumis?
Alumis reports financial results in USD
What is the latest annual profit for Alumis?
The latest annual profit of Alumis is USD -154.99M
What is the registered address of Alumis?
The registered address for Alumis is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Alumis website address?
The website address for Alumis is www.alumis.com
Which industry sector does Alumis operate in?
Alumis operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AGMHAGM Group Holdings Inc
US$ 0.1818
(77.71%)
130.81M
GVVisionary Holdings Inc
US$ 6.34
(71.58%)
25.73M
AFRIForafric Global PLC
US$ 14.13
(58.94%)
9
HFBLHome Federal Bancorp Inc of Louisiana
US$ 19.82
(53.41%)
63
PSTVPlus Therapeutics Inc
US$ 0.518
(48.00%)
7.22M
GEOSGeospace Technologies Corporation
US$ 5.01
(-32.21%)
1
RANDRand Capital Corporation
US$ 17.01
(-23.96%)
1
BSCUInvesco BulletShares 2030 Corporate Bond ETF
US$ 13.01
(-21.53%)
1
PODCPodcastOne Inc
US$ 1.40
(-20.00%)
101
DCTHDelcath Systems Inc
US$ 10.81
(-19.51%)
7
AGMHAGM Group Holdings Inc
US$ 0.1818
(77.71%)
130.81M
GVVisionary Holdings Inc
US$ 6.34
(71.58%)
25.73M
CUTRCutera Inc
US$ 0.154
(33.33%)
23.26M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 11.56
(-4.70%)
8.01M
PSTVPlus Therapeutics Inc
US$ 0.518
(48.00%)
7.22M

Discussion

View Full Feed
Checkmate 36 Checkmate 36 4 minutes ago
Happy,
100% agree.

This is NWBO’s chance.
There has been a number of frustrated (some more than others) longs who have been left scratching their heads wondering….why????

Why not PR this or that?
Why not submit to NICE, FDA, EU?
Why not do
NWBO
ANTI-BAGHOLDER ANTI-BAGHOLDER 5 minutes ago

Purchase agreement for $165 million completed 
https://www.otcmarkets.com/otcapi/company
BBLC
Huggy Bear Huggy Bear 5 minutes ago
More converted shares raining down alert.

Gee, who keeps saying all this dilution is ending - while clearly it is not?
HMBL
uranium-pinto-beans uranium-pinto-beans 5 minutes ago
Seaport Research analyst Kenneth Zener upgraded five homebuilder stocks to Buy - raising KB Home (KBH) with a $79 price target, Lennar (LEN) with a $154 price target, TRI Pointe (TPH) with a $41 price target, M/I Homes (MHO) with a $151 price target and D.R. Horton (DHI) with a $164 price target - w
DHI KBH
uranium-pinto-beans uranium-pinto-beans 6 minutes ago
Todays largest decreases in stock option open interest $NVDA $SOFI $NOK $WFC $TSLA $MSTR $AMZN $BAC $LCID
AMZN BAC LCID
dennisdave dennisdave 6 minutes ago
Past doesn't matter, it doesnt?? ooh wow I will tell my wife this next time I forget to bring the kids to a soccer game
NWBO
HenryB3 HenryB3 6 minutes ago
Keep drinking the Kool aide. See you at 12 cents. Then what will be the story and year then?
ELTP
Carico13 Carico13 6 minutes ago
IMO SYTA is going to take off today. Get in while it's cheap
SYTA
ilovetech ilovetech 6 minutes ago
UCLA researchers unite to develop immunotherapy they hope will transform ovarian cancer treatment March 5, 2025
Key takeaways : (AI Analysis of potential synergy with DCVax technology below)

https://x.com/peter_brit/status/1897575005057130653?t=e1EFma2z-J3ISOx18TOzyw&s=19
NWBO
HappyLibrarian HappyLibrarian 8 minutes ago
As soon as MHRA approval hits which could be before month’s end (more likely) or could be as long as 3 months more (far less likely but this is NWBO so big delays due to reasons we are kept in dark about can never be off the table).
NWBO
FlyFishingStocks FlyFishingStocks 8 minutes ago
This is the end game I have been posting since Denner took the reigns. Sarissa has profited by trading mirror image moves in AMRN since Denner took over. They engineered bogus upgrades/ rallies so that they could stomp on retail euphoria and take the price down step by step toward this day.
AMRN
resx18 resx18 8 minutes ago
Let's keep this train rolling! $CBDW
CBDW
gdog gdog 8 minutes ago
Rr4627
26m

$NLST Good thing we did not hold our breath, Charls Schwab now shows earnings 3/12/25, we will see.( good things take time?)

1


1
NLST
buysellrepeat buysellrepeat 9 minutes ago
I really don’t think they are diluting us
ATWT
KISSINGER KISSINGER 9 minutes ago
Maybe the last 5 times I have explained to you and everyone here did not resonate strongly enough. CG puts his money directly into the company. Not into the hands of some short term flipper that needs optics as he has said to me in the past. If he follwed that philosophy there would be no company.
AHRO
Dr Speculator Ninja Dr Speculator Ninja 9 minutes ago
Choo-Choo! "Get your tickets for the Bitter Train!" Choo-Choo!

Awww HenryB3, you should have bought at .16..... If you'd only bought $ELTP when you first posted here on August 21, 2024 you would have more than doubled your money and been sitting pretty for the next leg up! But now it
ELTP
TheDane TheDane 9 minutes ago
Exactly…. “Others may have short term tariff worries

but the big tech companies doing so much

spending already have the correct change...”
SMCI
Stinger2014 Stinger2014 9 minutes ago
And the dump back to -.30…
BTOG
Bearslayer Bearslayer 11 minutes ago
If numbers are coming next week shouldn't they have put out a pr about the conference call they touted in the December pr?
NXPL
Paulie Pennies Paulie Pennies 11 minutes ago
The problem is they have fiduciary responsibilities they solved a good chunk of that over the last six months paying debt... from a non emotional standpoint and strictly speaking from a business perspective I don't see how they have any other choice and responsibility to shareholders to engage in a
ASII
stocktowatch stocktowatch 12 minutes ago
$CVM News! CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment

Full enrollment expected by Q2 2026 with plans to seek early approval at that time based o
CVM
TrendTrade2016 TrendTrade2016 12 minutes ago
SING HO HUM XI WONG TONG
drugrunner drugrunner 12 minutes ago
Wow look at the sad librarian /LC I'm not invested 082...  doing their best to create more false narratives POST UK APPROVAL


THE MILESTONE they claimed would never happen is now virtually accepted by the BASHERS now they are creating new narratives they have to have a partners
NWBO

Your Recent History

NASDAQ
ALMS
Alumis
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads